Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ranking study of investigational RSV vaccine formulations in healthy women
2016-001135-12Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus disease (RSV) (4 arms), sponsored by GSK. Primary endpoint: Number of subjects with grade 2 and grade 3 solicited general adverse events. Started Aug 2016; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2016-001135-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001135-12.